Calreticulin arms NK cells against leukemia.

Fucikova, Jitka; Kline, Justin P; Galluzzi, Lorenzo; Spisek, Radek

Fucikova, Jitka; Kline, Justin P; Galluzzi, Lorenzo; Spisek, Radek.

Afiliação

Fucikova J; Sotio, Prague, Czech Republic.
Kline JP; Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
Galluzzi L; Deparment of Medicine, University of Chicago, Chicago, IL, USA.
Spisek R; Committee on Immunology, Univesity of Chicago, Chicago, IL, USA.

Oncoimmunology ; 9(1): 1671763, 2020.

Article em En | MEDLINE | ID: mdl-32002282

RESUMO

Calreticulin (CALR) exposed on the surface of cancer cells succumbing to therapy delivers robust phagocytic signals that support the activation of adaptive anticancer immune responses. Recent data from our group demonstrate that spontaneous CARL exposure on leukemic blasts also supports innate anticancer immunity by natural killer (NK) cells via an indirect mechanism relying on myeloid CD11c+CD14+ cells.

Assuntos

Leucemia; Rabdomiossarcoma Alveolar; Calreticulina/metabolismo; Humanos; Células Matadoras Naturais/metabolismo; Leucemia/terapia

Palavras-chave

Anticancer immunity; CCR7; CD80; IL15; MHC Class II; immunogenic cell death; type I IFN

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia / Rabdomiossarcoma Alveolar Limite: Humans Idioma: En Revista: Oncoimmunology Ano de publicação: 2020 Tipo de documento: Article País de afiliação: República Tcheca País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google